Trial Comparing Two Strategies of Chemotherapy for Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
The standard treatment of metastatic colorectal cancer is based on systemic chemotherapy.
Several effective drugs are currently available and can be administered either sequentially
or in combination. Most patients receive 2 or 3 lines of chemotherapy. The aim of this
randomized trial is to evaluate the potential benefit of a bitherapy with 5-fluorouracil
(5-FU) and oxaliplatin as first line chemotherapy compared with a sequential chemotherapy
with 5-FU alone as first line chemotherapy followed by the combination of 5-FU with
oxaliplatin in case of progressive disease, in terms of progression-free survival and overall
survival in patients with advanced colorectal cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Gustave Roussy, Cancer Campus, Grand Paris
Collaborators:
Fondation Francaise de Cancerologie Digestive Sanofi